betamethasone dipropionate
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | DIPROLENE AF | — | 2001-10-03 – 2006-08-28 | fda.gov ↗ |
| Label expansion | US (FDA) | DIPROSONE | — | 1982-07-21 | fda.gov ↗ |
| Approved | US (FDA) | DIPROSONE | — | 1975-01-29 | fda.gov ↗ |
Trials 60 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03898583 | Apr → Oct 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03892564 | Feb → Mar 2019 | phototoxic dermatitis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03899064 | Feb → Apr 2019 | photoallergic dermatitis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03476746 | Mar → Jul 2018 | — | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03442244 | Jan → Feb 2018 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02355639 | Jan → Apr 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01946386 | Sep → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01837576 | Apr → Jun 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01466478 | Nov → Dec 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05220293 | Feb 2022 → Dec 2023 | chronic rhinosinusitis | Oticara Australia PTY LTD | Terminated | No outcome recorded |
| Phase 1/2 | NCT01768013 | Jul → Oct 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT05882903 | Aug 2023 → Jun 2025 overdue | chronic rhinosinusitis | Oticara Australia PTY LTD | Recruiting | No outcome recorded |
| Phase 2 | NCT04580537 | Oct 2020 → Jun 2021 | psoriasis | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03819218 | Dec 2018 → Dec 2020 | psoriasis | MC2 Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT03462927 | Feb → Aug 2018 | psoriasis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03026478 | May 2016 → Mar 2018 | lichen planus, oral | Garlapati Komali | Unknown | No outcome recorded |
| Phase 2 | NCT02070965 | Jan → Oct 2014 | psoriasis | Primus Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01229098 | Oct 2010 → Sep 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01120223 | May 2010 → Aug 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01083758 | Apr 2010 → Aug 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00817219 | Jul 2009 → Dec 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00875277 | Apr → May 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00910676 | Oct 2007 → Mar 2009 | colorectal cancer, non-small cell lung carcinoma | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 2 | NCT00820950 | May 2007 → Jan 2009 | psoriasis | Incyte Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00263718 | Dec 2005 → May 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT02582177 | Jun 2019 → Jan 2020 | tinea infection | Ache Laboratorios Farmaceuticos S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03802344 | Dec 2018 → Oct 2019 | psoriasis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03731091 | Oct 2018 → Mar 2020 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02668692 | Feb → Jun 2016 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT02527421 | Aug 2015 → Mar 2019 | psoriasis | Primus Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02132936 | Jun 2014 → Feb 2015 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01947491 | Nov 2013 → Jan 2015 | psoriasis | Primus Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01866163 | Jun → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00279162 | Dec 2005 → Jul 2007 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00243464 | Sep 2005 → May 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216879 | Feb 2005 → Jul 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216840 | Dec 2004 → Sep 2005 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216827 | Nov 2004 → Sep 2005 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT04227288 | Nov 2021 → Oct 2023 | psoriasis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT05175001 | May 2021 → Jun 2022 | chronic pain syndrome | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 4 | NCT04555707 | Jun 2020 → Jun 2021 | psoriasis | Derm Research, PLLC | Unknown | No outcome recorded |
| Phase 4 | NCT04372277 | Apr 2020 → Mar 2021 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT04073069 | Sep 2019 → Aug 2020 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04114097 | Aug 2019 → Mar 2021 | atopic eczema | Jacob Thyssen | Completed | No outcome recorded |
| Phase 4 | NCT03827876 | Jan → Sep 2019 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT03506477 | May 2018 → Sep 2019 | psoriasis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT03848871 | Dec 2017 → Nov 2018 | psoriasis | Derm Research, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT03080545 | May → Oct 2017 | psoriasis | Psoriasis Treatment Center of Central New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT02749799 | Feb → Jul 2016 | psoriasis | Primus Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02004574 | Oct 2013 → Jun 2014 | psoriasis | Jooheung Lee | Completed | No outcome recorded |
| Phase 4 | NCT01761019 | Jan 2013 → Sep 2014 | psoriasis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00248456 | Oct 2005 → Feb 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07626463 | May 2026 → May 2027 expected | acute cholecystitis | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07337772 | Feb 2026 → Nov 2028 expected | adrenal cortex disorder, osteoarthritis, knee | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| — | NCT06344403 | Jun 2025 → Oct 2026 expected | herpes zoster | Beijing Tiantan Hospital | Active not recruiting | No outcome recorded |
| — | NCT06785350 | Jan → Sep 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06321354 | Jul → Nov 2024 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT05926895 | Jun 2023 → Aug 2024 | shoulder impingement syndrome | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT05303766 | Apr 2022 → Mar 2023 | osteoarthritis, knee | Assiut University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 39 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03758365 Comparator | Nov 2018 | vascular disorder | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03880357 Comparator | Oct 2018 → Mar 2019 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02376049 Comparator | Feb → Jul 2015 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03399526 Comparator | Feb → May 2013 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07256834 Comparator | Nov → Dec 2025 overdue | — | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06332612 Comparator | Aug → Dec 2024 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03279796 Comparator | Oct 2018 → Dec 2019 | epicondylitis, rotator cuff syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT02518048 Comparator | Aug 2015 → Jan 2016 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02416258 Comparator | Apr → Jun 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01347255 Comparator | May → Jun 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02920658 Comparator | Dec 2010 → Nov 2013 | aphthous stomatitis, lichen planus, oral | Ivan Alajbeg | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05981118 Comparator | Jul 2024 → Jul 2026 overdue | — | Wake Forest University Health Sciences | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT04071106 Comparator | Sep → Dec 2019 | psoriasis | Zagazig University | Unknown | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT05983445 Comparator | Jan 2023 → Apr 2024 | gout | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03806790 Comparator | Jan → Jun 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT04000932 Comparator | Jul 2018 → Dec 2019 | carpal tunnel syndrome | Baskent University | Unknown | No outcome recorded |
| Phase 3 | NCT03331523 Comparator | Oct 2017 → Oct 2018 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02899962 Comparator | Feb 2017 → Jun 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01422434 Comparator | Jul 2011 → Apr 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01188928 Comparator | Sep 2010 → Mar 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07635043 Comparator | Aug → Oct 2026 expected | psoriasis | Pakistan Institute of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07242846 Comparator | Oct → Nov 2025 | osteoarthritis, knee | Nigde Omer Halisdemir University | Completed | No outcome recorded |
| Phase 4 | NCT05475808 Comparator | Aug 2022 → Jul 2023 overdue | carpal tunnel syndrome | Abant Izzet Baysal University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05260125 Comparator | Mar 2022 → Mar 2025 overdue | hemiplegia, stroke disorder | Abant Izzet Baysal University | Recruiting | No outcome recorded |
| Phase 4 | NCT04207931 Comparator | Apr 2018 → Nov 2026 expected | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT03368274 Background | Sep 2017 → Jun 2018 | immunoglobulin G4-related sclerosing disease | Wen Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT02858713 Background | Jan → Apr 2017 | — | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02833545 Comparator | Sep 2016 → May 2018 | osteoarthritis, knee | Rabin Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03196817 Comparator | Aug 2016 → May 2017 | carpal tunnel syndrome | Hospital Alvorada | Unknown | No outcome recorded |
| Phase 4 | NCT01707043 Comparator | Oct 2012 → Sep 2013 | psoriasis | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00437255 Comparator | Aug 2006 → Jun 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07626489 Comparator | May 2026 → May 2027 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07002892 Comparator | Jan 2025 → Jan 2026 overdue | carpal tunnel syndrome | Yunus Burak Bayır | Recruiting | No outcome recorded |
| — | NCT06599086 Comparator | Sep 2024 → Sep 2025 overdue | carpal tunnel syndrome | Yunus Burak Bayır | Recruiting | No outcome recorded |
| — | NCT06011083 Comparator | Aug 2022 → Feb 2023 | psoriasis | Assiut University | Completed | No outcome recorded |
| — | NCT05556122 Background | Jul → Dec 2022 | peripheral nerve lesion | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| — | NCT04444726 Background | Jan 2019 → Nov 2020 | atopic eczema | Cairo University | Completed | No outcome recorded |
| — | NCT03525522 Comparator | Jan 2016 → May 2018 | lichen sclerosus et atrophicus | Dr Adolf Lukanovič | Unknown | No outcome recorded |
| — | NCT01413477 Comparator | Aug 2011 → Feb 2012 | allergic contact dermatitis | University of British Columbia | Unknown | No outcome recorded |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betamethasone Dipropionate | “The combination topical suspension of calcipotriene 0.005% and betamethasone dipropionate 0.064% is a first-line treatment for moderate to severe psoriasis vulgaris and is FDA...” NCT01761019 ↗80“1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from...” NCT05475808 ↗ “fixed-dose combination calcipotriol 50 μg/g + betamethasone dipropionate 0.5 mg/g (Cal/BD) cutaneous foam has been approved (Enstilar®, LEO Pharma) in the USA and EU for the...” PMID 32785881 ↗ Aug 2020 “A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0.05%; Promius Pharma, LLC; Princeton, New Jersey, USA) has...” PMID 29657667 ↗ Apr 2018 “1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone...” NCT03279796 ↗ “A foam formulation of calcipotriol and betamethasone dipropionate (Cal/BD foam), consisting of calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g, is approved for the...” PMID 32965655 ↗ Sep 2020 “Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical...” NCT01707043 ↗ “The two-compound topical suspension/gel containing calcipotriene plus betamethasone dipropionate is effective and safe in the treatment of psoriasis on the body and scalp...” PMID 23986161 ↗ Aug 2013 “All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone...” NCT01413477 ↗ “Calcipotriene Plus Betamethasone Dipropionate Gel Compared to the Gel Vehicle in Scalp Psoriasis, in Patients Receiving Calcipotriene Plus Betamethasone Dipropionate Ointment...” NCT00279162 ↗ “The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be...” NCT04000932 ↗ “This study will evaluate the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in...” NCT03506477 ↗ “For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml...” NCT05260125 ↗ “After the cannula needle was inserted to the articular cavity, 1 mL compound betamethasone (2 mg betamethasone sodium phosphate and 5 mg betamethasone dipropionate) was injected.” NCT05303766 ↗ “Effect of Calcipotriol Plus Betamethasone Dipropionate Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) With Scalp Psoriasis” NCT01083758 ↗ “The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml” NCT05556122 ↗ “Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.” PMID 27995521 ↗ Apr 2017 “Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage.” NCT02582177 ↗ “The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle” NCT01837576 ↗ “Each patient will receive 2 ml:(1 ml betamethasone dipropionate+1ml saline) perineural injection into the median nerve under US guidance, for 1 session.” NCT07002892 ↗ “Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)” NCT04580537 ↗ “The pharmacokinetics of LEO 90105 (calcipotriol hydrate plus betamethasone dipropionate) in Japanese subjects with extensive psoriasis vulgaris.” NCT01768013 ↗ “LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g).” NCT03476746 ↗ “Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients” NCT04372277 ↗ “Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents” NCT03080545 ↗ “LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g” NCT03442244 ↗ “Safety and Efficacy of Calcipotriol Plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis” NCT01120223 ↗ “Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation” NCT03899064 ↗ “Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)” NCT03880357 ↗ “MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation” NCT03892564 ↗ “Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream” NCT03758365 ↗ “topical betamethasone dipropionate or calcipotriol cream twice daily for 12 weeks” NCT04071106 ↗ “Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064%” NCT03827876 ↗ “MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)” NCT03819218 ↗ “MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream” NCT03802344 ↗ “each vial contains betamethasone 5 mg + betamethasone dipropionate 2 mg” NCT07337772 ↗ “MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)” NCT03462927 ↗ “calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam” NCT03848871 ↗ “Enstilar Foam (Calcipotriene and Betamethasone Dipropionate)” NCT04227288 ↗ “Clobetasol, Betamethasone Dipropionate, or Fluocinonide” NCT04207931 ↗ “DFD-01 (betamethasone dipropionate) Spray, 0.05%” NCT02527421 ↗ “betamethasone dipropionate 0.643 mg/g” NCT02668692 ↗ “betamethasone dipropionate 0.643 mg/g” NCT03806790 ↗ “* betamethasone dipropionate 0.05%” NCT01313221 ↗ “Betamethasone dipropionate” NCT03898583 ↗ |
| Known as | BD spray 0.05% | “A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0.05%; Promius Pharma, LLC; Princeton, New Jersey, USA) has...” PMID 29657667 ↗ Apr 2018 |
| Known as | BDP | “combination of calcipotriene (CAL) and betamethasone dipropionate (BDP)” PMID 37490268 ↗ Jul 20231“calcipotriene \[CAL\]/betamethasone dipropionate \[BDP\] ointment” NCT03462927 ↗ |
| Known as | betamethasone | “A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily...” NCT01229098 ↗2“LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)” NCT01866163 ↗ “Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)” NCT03462927 ↗ |
| Known as | Betamethasone diproprionate (0.5% ointment USP generic) | “Betamethasone diproprionate (0.5% ointment USP generic)” NCT01413477 ↗ |
| Known as | Betamethasone-17,21-dipropionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01188928 ↗ |
| Known as | Betnovate | “Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid ("Betnovate", betamethasone dipropionate ointment 0.1%) and placebo” NCT04114097 ↗ |
| Known as | BMDP CREAM | “To assess the safety and efficacy of one (single) application of Betamethasone Dipropionate Nasal Cream (BMDP CREAM) onto the sinus mucosa.” NCT05882903 ↗ |
| Known as | Calcipotriol/betamethasone dipropionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02004574 ↗ |
| Known as | Daivobet | “Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the...” PMID 17135738 ↗ 2006 |
| Known as | DFD-01 | “DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.” NCT02749799 ↗2“DFD-01 (betamethasone dipropionate) Spray, 0.05%” NCT02527421 ↗ “DFD-01 (Betamethasone Dipropionate) Spray 0.05%” NCT02070965 ↗ |
| Known as | diprolene | “Topical medical treatment (Betamethasone dipropionate 0.05% " diprolene " )” NCT04444726 ↗ |
| Known as | Diprolene AF | “Diprolene® AF betamethasone dipropionate 0.05% cream.” NCT00820950 ↗ |
| Known as | Diprosone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525522 ↗ |
| Known as | Diprospan | “Thus, the investigators suppose that pre-emptive scalp infiltration with steroid (diprospan) plus local anesthetic (ropivacaine) could relieve postoperative pain after...” NCT04073069 ↗10“Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.” NCT03368274 ↗ “Lidocaine mixed with diprospan injected into tender points.” NCT06344403 ↗ “Injection of steroids (diprospan) intra articularly” NCT02833545 ↗ |
| Known as | Dovobet | “Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the...” PMID 17135738 ↗ 2006 |
| Known as | Rinderon - DP | “Rinderon® - DP = betamethasone dipropionate” NCT01422434 ↗ |
| Known as | Sernivo | “A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0.05%; Promius Pharma, LLC; Princeton, New Jersey, USA) has...” PMID 29657667 ↗ Apr 2018 |
| Known as | Sernivo (betamethasone dipropionate, 0.05%) Spray | “Sernivo (betamethasone dipropionate, 0.05%) Spray” NCT02749799 ↗ |
| Known as | Taclonex | “Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the...” PMID 17135738 ↗ 2006 |
| Modality | Small molecule | “Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema.” NCT01413477 ↗ |
| Route | Topical | “once daily topical treatment for up to 8 weeks” NCT00216840 ↗ |